Workshop on development of new antibacterial medicines

  • Email
  • Help

Details

TitleWorkshop on development of new antibacterial medicines
Date25/10/2012 - 26/10/2012
LocationEuropean Medicines Agency, London, UK
SummaryThis workshop's aim is to discuss aspects of the development of antibacterial medicinal products, including those targeting multiple-drug-resistant pathogens and with narrow-action spectra and discussion on specific indications. Participation is invitation-based only.

All documents

Name Language First published Last updated
Agenda – Workshop on development of new antibacterial medicines (English only) 23/10/2012 24/10/2012
Report - Workshop on development of new antibacterial medicines (English only) 25/09/2013  
Presentation - Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) (Marco Cavaleri) (English only) 25/09/2013  
Presentation - 2012 addendum to the EU guideline on antibacterial agents (Mair Powell) (English only) 25/09/2013  
Presentation - Bridging the bench to bedside divide: Optimal dosing regimens of novel antimicrobials against multi drug resistant (MDR) pathogens (George Drusano) (English only) 25/09/2013  
Presentation - Antibiotic development for resistant bacteria: A Pharmacometric-based solution (Paul Ambrose) (English only) 25/09/2013  
Presentation - Superiority and organism-specific clinical trials of anitbacterial agents (Helen Boucher) (English only) 25/09/2013  
Presentation - Treatment of serious infections due to multiple drug resistant (MDR) acinetobacter baumannii: Presentation of a multicenter randomised clinical trial (Riccardo Utili) (English only) 25/09/2013  
Presentation - Drugs for multiple drug resistant (MDR) pathogens: Issues in development (Mark Goldberger) (English only) 25/09/2013  
Presentation - Issues to address for a Tier B development plan (Barry Eisenstein) (English only) 25/09/2013  
Presentation - Issues to address for a Tier C development (Aaron Dane) (English only) 25/09/2013  
Presentation - Considerations in the development of beta-lactamase inhibitor combination products for multiple drug resistant (MDR) pathogens (Michael Dudley) (English only) 25/09/2013  
Presentation - Challenges to develop diagnostics for treatment of multiple drug resistant (MDR) pathogens (Herman Goossens) (English only) 25/09/2013  
Presentation - Diagnostics: A focus on use in development of drugs for multiple drug resistant (MDR) pathogens (John Rex) (English only) 25/09/2013  
Presentation - Guidelines HAP/VAP: Standpoint from (some) academics (Serge Kouzan) (English only) 25/09/2013  
Presentation - HAP-VAP (David Friedland) (English only) 25/09/2013  
Presentation - Clinical trials in community-acquired pneumonia (CAP) (Francesco Blasi) (English only) 25/09/2013  
Presentation - Community-acquired pneumonia (CAP) (Keith Barker) (English only) 25/09/2013  
Presentation - Bacteraemia or severe sepsis as indication? (Bart Rijnders) (English only) 25/09/2013  
Presentation - Development of drugs for bacteremia (Charles Knirsch) (English only) 25/09/2013  
Presentation - Eradication of carriage (Jan Kluytmans) (English only) 25/09/2013  
Presentation - Development of drugs for eradication of nasal carriage of s. aureus to reduce s. aureus infections in vulnerable surgical patients (Richard Bax) (English only) 25/09/2013  
Presentation - Inhaled antibiotics in non-CF (Michael Loebinger) (English only) 25/09/2013  
Presentation - Inhalational antibacterial regimens in non-cystic fibrosis patients (Jeff Alder) (English only) 25/09/2013  

Media Videos